6.1.2 Issues of bioavailability, dosage, and long-term safety Low bioavailability is a primary barrier to using flavonoids as a therapy
That's a genuinely significant development in obesity medicine, and it's the reason GLP-1 therapy has moved from "cosmetic weight loss medication" to "cardiometabolic treatment" in clinical guidelines
If youre paying out-of-pocket, compounded GLP-1 providers like TrimRx offer the most affordable access, with monthly costs starting at $199 versus $900+ for brand-name medications through other programs
They might review the frequency of your treatments or explore other factors that could be contributing to this reaction
On January 8, 2026, the Thirteenth Amendment facilitated the payoff of the Company's then-outstanding accounts receivable securitization facility, following an extension of that facility's maturity from December 1, 2025 to January 9, 2026